Arthur I Sagalowsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6875941/publications.pdf

Version: 2024-02-01

71 papers

1,755 citations

279798 23 h-index 289244 40 g-index

84 all docs 84 docs citations

84 times ranked 2546 citing authors

#	Article	IF	CITATIONS
1	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World Journal of Urology, 2021, 39, 491-500.	2.2	2
2	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e11-736.e18.	1.6	8
3	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer, 2020, 126, 4362-4370.	4.1	14
4	The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States Cancer Management and Research, 2020, Volume 12, 9825-9836.	1.9	3
5	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 604.e9-604.e17.	1.6	77
6	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. Journal of Clinical Medicine, 2020, 9, 1218.	2.4	5
7	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2019, 37, 2419-2427.	2.2	9
8	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients Journal of Clinical Oncology, 2019, 37, 651-651.	1.6	0
9	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients Journal of Clinical Oncology, 2019, 37, e16100-e16100.	1.6	О
10	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology, 2018, 112, 103-111.	1.0	15
11	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 159.e7-159.e17.	1.6	21
12	Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 14.e7-14.e15.	1.6	55
13	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e11-88.e18.	1.6	15
14	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. European Urology Oncology, 2018, 1, 242-251.	5.4	14
15	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	1.6	4
16	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 91-100.	0.8	67
17	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. Journal of Urology, 2017, 198, 1021-1026.	0.4	2
18	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 197, 580-589.	0.4	35

#	Article	IF	CITATIONS
19	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. Journal of Urology, 2017, 197, 1208-1213.	0.4	45
20	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. Bladder Cancer, 2016, 2, 91-99.	0.4	8
21	Targeting XBP1-mediated \hat{l}^2 -catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. Oncotarget, 2016, 7, 56842-56854.	1.8	24
22	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15Ayear experience and lessons learned. BMC Urology, 2016, 16, 43.	1.4	24
23	Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. Urology, 2016, 96, 44-53.	1.0	10
24	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non–muscle-invasive high-grade bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 485.e7-485.e14.	1.6	19
25	Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?. Journal of Adolescent and Young Adult Oncology, 2016, 5, 248-253.	1.3	3
26	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. Journal of Urology, 2016, 196, 321-326.	0.4	14
27	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. World Journal of Urology, 2016, 34, 105-112.	2.2	7
28	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 268.e1-268.e7.	1.6	24
29	Editorial Comment. Journal of Urology, 2015, 194, 329-329.	0.4	0
30	Editorial Comment. Urology, 2015, 85, 867-868.	1.0	2
31	Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer. Urology, 2015, 85, 876-882.	1.0	27
32	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. Urology, 2015, 86, 1146-1152.	1.0	25
33	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. BMC Urology, 2015, 15, 24.	1.4	11
34	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World Journal of Urology, 2015, 33, 1965-1972.	2.2	9
35	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e21-18.e26.	1.6	8
36	Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes. Nature Genetics, 2015, 47, 13-21.	21.4	310

#	Article	IF	Citations
37	Editorial Comment. Urology, 2014, 84, 1334.	1.0	O
38	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tractâ€"ls There Evidence for Discordant Biology?. Journal of Urology, 2014, 191, 926-931.	0.4	29
39	Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e23-30.e28.	1.6	24
40	Dysregulation of \hat{I}^2 -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 191, 1671-1677.	0.4	22
41	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2014, 191, 28-34.	0.4	35
42	Is Extended Lymphadenectomy of Beneficial Therapeutic Value for T2 Urothelial Cancer?. Journal of Urology, 2014, 191, 1206-1208.	0.4	1
43	Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors. Journal of Urology, 2014, 191, 1485-1490.	0.4	19
44	Editorial Comment. Urology, 2014, 83, 398-399.	1.0	1
45	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 379-385.	1.9	27
46	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 981-988.	1.6	39
47	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	1.0	18
48	Editorial Comment. Urology, 2014, 84, 363.	1.0	0
49	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 54.e19-54.e26.	1.6	31
50	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. Journal of Urology, 2014, 192, 1050-1056.	0.4	76
51	Re: A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2013, 63, 579-580.	1.9	2
52	Risk of adverse cardiovascular events (CVE) and incident diabetes mellitus (DM) in patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT): A meta-analysis of adjusted observational results Journal of Clinical Oncology, 2012, 30, e15192-e15192.	1.6	0
53	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC) Journal of Clinical Oncology, 2012, 30, TPS4678-TPS4678.	1.6	O
54	Editorial Comment. Journal of Urology, 2009, 182, 1487-1487.	0.4	0

#	Article	IF	Citations
55	Editorial Comment on: Efficacy and Safety of TachoSil \hat{A}^{\otimes} as Haemostatic Treatment versus Standard Suturing in Kidney Tumour Resection: A Randomised Prospective Study. European Urology, 2007, 52, 1162-1163.	1.9	7
56	StoneA. and KrederK.J.: Urinary Diversion: Scientific Foundations and Clinical Practice. New York: Taylor & Francis2004. 400 pages Journal of Urology, 2006, 175, 1579-1580.	0.4	0
57	Cobalamin Profiles In Patients After Urinary Diversion. Journal of Urology, 2002, 167, 1696-1700.	0.4	20
58	Radio Frequency Ablation Induced Acute Renal Failure. Journal of Urology, 2002, 168, 186-186.	0.4	6
59	Cobalamin profiles in patients after urinary diversion. Journal of Urology, 2002, 167, 1696-700.	0.4	5
60	Expression of the RNA component of human telemorase (hTR) in ThinPrepâ® preparations from bladder washings. Cancer, 2001, 93, 73-79.	4.1	6
61	THE GROWTH INHIBITORY EFFECT OF p21 ADENOVIRUS ON HUMAN BLADDER CANCER CELLS. Journal of Urology, 2000, 163, 1033-1038.	0.4	35
62	Early Results with Split-Cuff Nipple Ureteral Reimplants in Urinary Diversion. Journal of Urology, 1995, 154, 2028-2031.	0.4	24
63	Factors Influencing Adrenal Metastasis in Renal Cell Carcinoma. Journal of Urology, 1994, 151, 1181-1184.	0.4	129
64	Testicular Tumors in Men with Human Immunodeficiency Virus. Journal of Urology, 1992, 147, 1038-1040.	0.4	59
65	Long-Term Patient Survival after Cystectomy For Regional Metastatic Transitional Cell Carcinoma of the Bladder. Journal of Urology, 1991, 146, 36-39.	0.4	101
66	Re: Primary Signet Ring Cell Adenocarcinoma of the Bladder, M. L. Blute, D. E. Engen, W. D. Travis and L. K. Kvols, J. Urol, 141: 17–21, 1989. Journal of Urology, 1990, 143, 135-135.	0.4	0
67	Mechanisms of posttransplant hypertension. World Journal of Urology, 1989, 7, 102-110.	2.2	4
68	Uncommon sites of recurrent seminoma and implications for therapy. Cancer, 1986, 57, 1060-1065.	4.1	18
69	Urologic Complications in 505 Renal transplants with Early Catheter Removal. Journal of Urology, 1983, 129, 929-932.	0.4	56
70	Signet Ring Cell Carcinoma of the Bladder. Journal of Urology, 1983, 130, 368-368.	0.4	4
71	Renal Transplantation in Diabetic Patients: The End Result Does Justify the Means. Journal of Urology, 1983, 129, 253-255.	0.4	6